#patent expiry

1 story

#business #eli lilly #finance #novo nordisk #ozempic #pharmaceutical #semaglutide #stock decline #wegovy #weight loss drugs

Novo's growth plan fails to impress investors
The Danish drugmaker's strategy to diversify beyond weight-loss drugs disappoints the market as patent expiry looms.
CNBC · 1m